Source: AstraZeneca From: pharmavoice.com AstraZeneca have announced that the US FDA has granted Priority Review for its experimental breast cancer treatment trastuzumab. The Prescription Drug User Fee Fact (PDUFA) date for trastuzumab deruxtecan, an HER-2 targeting antibody drug conjugate and potential new medicines for the treatment of HER2-positive metastic breast cancer is set for the second quarter of 2020. José …
Drug to Replace Chemotherapy May Reshape Cancer Care
By: Kanoko Matsuyama From: bloomberg.com * Promising treatment may reach far more breast cancer patients * Daiichi drug may outsell Roche’s Herceptin, spark dealmaking A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer …
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
From: PR Newswire — Breakthrough Therapy designation received for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1) — HER2-positive metastatic breast cancer often advances to the point where no currently approved HER2-targeted treatments continue to control the disease — Designation …